Genenta Science (NASDAQ: GNTA), a clinical-stage biotechnology company pioneering the development of hematopoietic stem progenitor cell immuno-gene therapy for solid tumors, including the lead product candidate, Temferon(TM), has closed on its upsized initial public offering. The offering was comprised of 2.4 million American Depositary Shares, or ADSs, with each one representing one ordinary share, offered at a public price of $11.50 per share. In addition, Genenta also sold 720,114 ordinary shares reserved for subscription; those were purchased by existing shareholders for $11.50 per share. According to the announcement, gross proceeds from the IPO reached approximately $36 million before typical deductions. Roth Capital Partners acted as sole book-running manager for the offering.
To view the full press release, visit https://ibn.fm/nRHlx
About Genenta Science S.p.A.
Genenta is a clinical-stage biotechnology company pioneering the development of a proprietary hematopoietic stem cell gene therapy for the treatment of a variety of solid tumor cancers. Temferon is based on ex-vivo gene transfer into autologous hematopoietic stem/progenitor cells (“HSPCs”) to deliver immunomodulatory molecules directly via tumor-infiltrating monocytes/macrophages (Tie2 Expressing Monocytes, TEMs). Temferon, which is under investigation in a phase 1/2a clinical trial in newly diagnosed glioblastoma multiforme patients who have an unmethylated MGMT gene promoter (“uMGMT-GBM”), is based on Genenta’s platform technology, which is not restricted to preselected tumor antigens nor type and may reach solid tumors, one of the main unresolved challenges in immuno-oncology. For more information, please visit www.Genenta.com.
About InvestorWire
InvestorWire is the wire service that gives you more. From regional releases to global announcements presented in multiple languages, we offer the wire-grade dissemination products you’ll need to ensure that your next press release grabs the attention of your target audience and doesn’t let go. While our competitors look to nickel and dime you with hidden fees and restrictive word limits, InvestorWire keeps things transparent. We offer UNLIMITED Words on all domestic releases. While other wire services may provide a basic review of your release, InvestorWire helps you put your best foot forward with complimentary Press Release Enhancement.
With our competitors, the work is done the second your release crosses the wire. Not with InvestorWire. We include follow-up coverage of every release by leveraging the ever-expanding audiences of the 50+ brands that make up the InvestorBrandNetwork.
Get more out of your next press release with InvestorWire. It’s unlike anything you’ve seen before.
For more information, please visit https://www.InvestorWire.com
Please see full terms of use and disclaimers on the InvestorBrandNetwork website applicable to all content provided by IBN, wherever published or re-published: http://ibn.fm/Disclaimer
InvestorWire (IW)
8033 Sunset Blvd Suite 1037-IW
Los Angeles, CA 90046
310.299.1717 Office
www.InvestorWire.com
[email protected]
InvestorWire is part of the InvestorBrandNetwork.